Cypralis (United Kingdom)
Cypralis is developing of a novel category of small molecule drugs that inhibit cyclophilins, a large family of proteins involved in many diseases. The company has IP on three distinct classes of small molecules that share potent inhibition of cyclophilins, span a wide range of molecular weights, solubility, specificity and PK properties. We use these compounds as tools to validate inhibition of cyclophilins as novel therapeutic approach to treat diseases and as starting points for specific medi
Basic Information
- Category: business
- Website: http://www.cypralis.com
Documented Facts
- Email: contact@cypralis.com (No linked source recorded for this statement.)
Evidence and Sources
- Cypralis (United Kingdom) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Cypralis (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/cypralis-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cypralis-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cypralis-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Cypralis is developing of a novel category of small molecule drugs that inhibit cyclophilins, a large family of proteins involved in many diseases. The company has IP on three distinct classes of small molecules that share potent inhibition of cyclophilins, span a wide range of molecular weights, solubility, specificity and PK properties. We use these compounds as tools to validate inhibition of cyclophilins as novel therapeutic approach to treat diseases and as starting points for specific medi
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.